ImmunityBio, Inc. IBRX Reportable Segment — Gross Profit
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s reportable segment — gross profit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s reportable segment — gross profit?
- ImmunityBio, Inc. (IBRX) reported reportable segment — gross profit of $43.97M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — gross profit changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — gross profit increased by 167.1% year-over-year, from $16.46M to $43.97M.
- What is the long-term trend for ImmunityBio, Inc.'s reportable segment — gross profit?
- Over 2 years (2023 to 2025), ImmunityBio, Inc.'s reportable segment — gross profit has grown at a 1245.1% compound annual growth rate (CAGR), from $622K to $112.54M.
- What does reportable segment — gross profit mean?
- The profit remaining after subtracting direct production costs from segment revenue.
- How do you interpret reportable segment — gross profit?
- Higher margins indicate strong pricing power or efficient manufacturing processes.
- How does reportable segment — gross profit compare across companies?
- Standard metric for evaluating the core profitability of a business unit.